Cumberland Pharmaceuticals Stock Performance
| CPIX Stock | USD 1.37 0.26 23.42% |
Cumberland Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cumberland Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cumberland Pharmaceuticals is expected to be smaller as well. Cumberland Pharmaceuticals right now shows a risk of 3.86%. Please confirm Cumberland Pharmaceuticals treynor ratio, as well as the relationship between the expected short fall and day median price , to decide if Cumberland Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Cumberland Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong forward indicators, Cumberland Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 2:1 | Last Split Date 2007-07-06 |
1 | Acquisition by Jones James of tradable shares of Cumberland Pharmaceuticals at 1.35 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Krogulski Kenneth of 250 shares of Cumberland Pharmaceuticals at 1.3 subject to Rule 16b-3 | 09/17/2024 |
3 | Acquisition by Krogulski Kenneth of 250 shares of Cumberland Pharmaceuticals at 1.29 subject to Rule 16b-3 | 09/19/2024 |
4 | Acquisition by Krogulski Kenneth of 250 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3 | 09/23/2024 |
5 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 1.22 subject to Rule 16b-3 | 09/24/2024 |
6 | Acquisition by Krogulski Kenneth of 197 shares of Cumberland Pharmaceuticals at 1.29 subject to Rule 16b-3 | 09/25/2024 |
7 | Acquisition by Krogulski Kenneth of 221 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3 | 09/27/2024 |
8 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3 | 09/30/2024 |
9 | Acquisition by Young Caroline of tradable shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3 | 10/11/2024 |
10 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.3 subject to Rule 16b-3 | 10/17/2024 |
11 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.28 subject to Rule 16b-3 | 10/18/2024 |
12 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3 | 10/21/2024 |
13 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.26 subject to Rule 16b-3 | 10/23/2024 |
14 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3 | 10/24/2024 |
15 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.23 subject to Rule 16b-3 | 10/25/2024 |
16 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.32 subject to Rule 16b-3 | 10/30/2024 |
17 | Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.2 subject to Rule 16b-3 | 10/31/2024 |
18 | Is Cumberland Pharmaceuticals Using Too Much Debt | 11/04/2024 |
19 | Cumberland Pharmaceuticals director James Jones buys 1,827 in stock | 11/05/2024 |
20 | CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | 11/06/2024 |
21 | Cumberland Pharmaceuticals Inc Reports Q3 2024 Revenue of 9.1 Million and EPS Loss of 0.11 | 11/07/2024 |
22 | Cumberland Pharmaceuticals Non-GAAP EPS of -0.02, revenue of 9.1M | 11/08/2024 |
23 | CPIX Stock Surges Amidst Volatility in Pharmaceutical Sector | 11/27/2024 |
| Begin Period Cash Flow | 19.8 M |
Cumberland |
Cumberland Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 135.00 in Cumberland Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of 2.00 from holding Cumberland Pharmaceuticals or generate 1.48% return on investment over 90 days. Cumberland Pharmaceuticals is currently generating 0.091% in daily expected returns and assumes 3.8557% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Cumberland, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cumberland Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cumberland Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cumberland Pharmaceuticals, and traders can use it to determine the average amount a Cumberland Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0236
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | CPIX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.86 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Cumberland Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cumberland Pharmaceuticals by adding it to a well-diversified portfolio.
Cumberland Pharmaceuticals Fundamentals Growth
Cumberland Stock prices reflect investors' perceptions of the future prospects and financial health of Cumberland Pharmaceuticals, and Cumberland Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cumberland Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 23.25 M | ||||
| Shares Outstanding | 14.04 M | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 0.63 X | ||||
| Price To Sales | 0.52 X | ||||
| Revenue | 39.55 M | ||||
| Gross Profit | 32.89 M | ||||
| EBITDA | 153.32 K | ||||
| Net Income | (6.28 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 6.09 M | ||||
| Earnings Per Share | (0.76) X | ||||
| Market Capitalization | 19.24 M | ||||
| Total Asset | 81.78 M | ||||
| Retained Earnings | (17.49 M) | ||||
| Working Capital | 7.73 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
About Cumberland Pharmaceuticals Performance
Evaluating Cumberland Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cumberland Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cumberland Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 277.32 | 332.50 | |
| Return On Tangible Assets | (0.11) | (0.10) | |
| Return On Capital Employed | (0.12) | (0.11) | |
| Return On Assets | (0.08) | (0.07) | |
| Return On Equity | (0.21) | (0.20) |
Things to note about Cumberland Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cumberland Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cumberland Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cumberland Pharmaceuticals may become a speculative penny stock | |
| Cumberland Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 39.55 M. Net Loss for the year was (6.28 M) with profit before overhead, payroll, taxes, and interest of 32.89 M. | |
| Cumberland Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| About 45.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: CPIX Stock Surges Amidst Volatility in Pharmaceutical Sector |
- Analyzing Cumberland Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cumberland Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cumberland Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cumberland Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cumberland Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cumberland Pharmaceuticals' stock. These opinions can provide insight into Cumberland Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.